Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel
- PMID: 16818928
- DOI: 10.7326/0003-4819-145-1-200607040-00009
Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel
Abstract
Background: Conflicting reports have caused controversy on whether cysticidal drugs modify the natural course of neurocysticercosis.
Purpose: To perform a meta-analysis of randomized trials assessing the effect of cysticidal drugs on neuroimaging and clinical outcomes of patients with neurocysticercosis.
Data sources: Search of MEDLINE, Cochrane Database of Systematic Reviews, and Literatura Latino-Americana y del Caribe en Ciencias de la Salud (LILACS) between 1979 and 2005. There were no language restrictions.
Study selection: Randomized trials of cysticidal drug therapy for neurocysticercosis that met predefined criteria designed to allow characterization of the disease and objective evaluation of therapy. The authors independently reviewed articles. Abstracted data included study design, number of randomly assigned patients and withdrawals, intervention, adverse events, timing of neuroimaging studies, and outcomes.
Data synthesis: Eleven studies met the inclusion criteria. Six trials randomly assigned 464 patients with cystic lesions (vesicular cysticerci), and 5 trials randomly assigned 478 patients with enhancing lesions (colloidal cysticerci). Parasites were located in the brain parenchyma or subarachnoid space at the convexity of the cerebral hemispheres. Cysticidal drug therapy was associated with complete resolution of cystic lesions (44% vs. 19%; P = 0.025). Trials on enhancing lesions showed a trend toward lesion resolution favoring the use of cysticidal drugs (72% vs. 63%; P = 0.38) that became statistically significant when an outlier trial was excluded from the analysis (69% vs. 55%; P = 0.006). Risk for seizure recurrence was lower after cysticidal treatment in patients with enhancing lesions (14% vs. 37%; P < 0.001). The single trial evaluating the frequency of seizures in patients with cystic lesions showed a 67% reduction in the rate of generalized seizures with treatment (P = 0.006).
Limitations: Not all studies focused on the control of seizures as an outcome.
Conclusions: Cysticidal drug therapy results in better resolution of colloidal and vesicular cysticerci, lower risk for recurrence of seizures in patients with colloidal cysticerci, and a reduction in the rate of generalized seizures in patients with vesicular cysticerci.
Comment in
-
Do patients with neurocysticercosis benefit from cysticidal therapy?Nat Clin Pract Neurol. 2007 Jan;3(1):22-3. doi: 10.1038/ncpneuro0378. Nat Clin Pract Neurol. 2007. PMID: 17205071 No abstract available.
Similar articles
-
Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial.J Child Neurol. 2022 Apr;37(5):366-372. doi: 10.1177/08830738221077762. Epub 2022 Feb 25. J Child Neurol. 2022. PMID: 35213246 Clinical Trial.
-
Anthelmintics for people with neurocysticercosis.Cochrane Database Syst Rev. 2021 Jun 1;6(6):CD000215. doi: 10.1002/14651858.CD000215.pub5. Cochrane Database Syst Rev. 2021. PMID: 34060667 Free PMC article.
-
Treating neurocysticercosis medically: a systematic review of randomized, controlled trials.Trop Med Int Health. 1999 Nov;4(11):713-8. doi: 10.1046/j.1365-3156.1999.00477.x. Trop Med Int Health. 1999. PMID: 10588764
-
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.Lancet Infect Dis. 2014 Aug;14(8):687-695. doi: 10.1016/S1473-3099(14)70779-0. Epub 2014 Jul 3. Lancet Infect Dis. 2014. PMID: 24999157 Free PMC article. Clinical Trial.
-
Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial.Pediatr Infect Dis J. 2009 May;28(5):403-6. doi: 10.1097/INF.0b013e31819073aa. Pediatr Infect Dis J. 2009. PMID: 19325515 Clinical Trial.
Cited by
-
Neurocysticercosis: Diagnostic problems & current therapeutic strategies.Indian J Med Res. 2016 Sep;144(3):319-326. doi: 10.4103/0971-5916.198686. Indian J Med Res. 2016. PMID: 28139530 Free PMC article. Review.
-
Neurocysticercosis: An Easy to Miss Diagnosis in Non-Endemic Regions.Cureus. 2020 Dec 13;12(12):e12066. doi: 10.7759/cureus.12066. Cureus. 2020. PMID: 33329988 Free PMC article.
-
Albendazole and Corticosteroids for the Treatment of Solitary Cysticercus Granuloma: A Network Meta-analysis.PLoS Negl Trop Dis. 2016 Feb 5;10(2):e0004418. doi: 10.1371/journal.pntd.0004418. eCollection 2016 Feb. PLoS Negl Trop Dis. 2016. PMID: 26849048 Free PMC article.
-
Albendazole and praziquantel combination versus albendazole alone in children with multiple neurocysticercosis: An open labelled randomized controlled trial.J Family Med Prim Care. 2024 Jun;13(6):2300-2304. doi: 10.4103/jfmpc.jfmpc_733_23. Epub 2024 Jun 14. J Family Med Prim Care. 2024. PMID: 39027868 Free PMC article.
-
Anthelmintics for people with neurocysticercosis.Cochrane Database Syst Rev. 2010 Mar 17;2010(3):CD000215. doi: 10.1002/14651858.CD000215.pub4. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2021 Jun 1;6:CD000215. doi: 10.1002/14651858.CD000215.pub5. PMID: 20238309 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous